Exercise intolerance during post-MI heart failure in rats: Prevention with supplemental dietary propionyl-L-carnitine

Stanley G. Koh, Daniel A. Brenner, Donna Hope Korzick, Marlena M. Tickerhoof, Carl S. Apstein, Kurt W. Saupe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Summary. Exercise capacity in patients with several types of cardiovascular disease can be improved with dietary carnitine, or carnitine derivatives. Mechanisms underlying this improvement remain largely unknown in part due to a lack of animal models of cardiac pathology in which carnitine derivatives improve exercise tolerance. Our goal was to evaluate the ability of propionyl-L-carnitine (PLC) to improve exercise tolerance in a rat model of exercise intolerance. Fischer 344 rats were followed after either a moderate size MI (n = 22) or sham MI surgery (n = 14). Starting 10 days post-surgery 10 of the MI and 7 of the sham rats received 100 mg/kg/day PLC in drinking water, which increased plasma and LV total 1-carnitine concentrations 15-23% (p < 0.05). Rats were followed longitudinally until a statistically significant decrease in exercise capacity occurred in one of the groups, at which time all rats were sacrificed for study of the isolated perfused hearts. At 12-weeks post-MI exercise capacity had decreased 16 ± 7% (p < 0.05) in the MI group, but remained within 3% of baseline in the MI group that received PLC and the sham groups. Both MI groups exhibited the same degree of LV dilation, decrease in fractional shortening, and blunting of the response to isoproterenol. We conclude that supplemental dietary PLC attenuates the exercise intolerance that occurs secondary to post-MI heart failure in rats, but that this beneficial effect is not attributable to altered LV remodeling, an improved response to β-adrenergic stimulation, or increased skeletal muscle citrate synthase activity.

Original languageEnglish (US)
Pages (from-to)7-14
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume17
Issue number1
DOIs
StatePublished - Aug 5 2003

Fingerprint

propionylcarnitine
Carnitine
Heart Failure
Exercise
Exercise Tolerance
Citrate (si)-Synthase
Inbred F344 Rats
Ambulatory Surgical Procedures
Isoproterenol

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Koh, Stanley G. ; Brenner, Daniel A. ; Korzick, Donna Hope ; Tickerhoof, Marlena M. ; Apstein, Carl S. ; Saupe, Kurt W. / Exercise intolerance during post-MI heart failure in rats : Prevention with supplemental dietary propionyl-L-carnitine. In: Cardiovascular Drugs and Therapy. 2003 ; Vol. 17, No. 1. pp. 7-14.
@article{8297afe16ded4647a6e8e29d5b706fbd,
title = "Exercise intolerance during post-MI heart failure in rats: Prevention with supplemental dietary propionyl-L-carnitine",
abstract = "Summary. Exercise capacity in patients with several types of cardiovascular disease can be improved with dietary carnitine, or carnitine derivatives. Mechanisms underlying this improvement remain largely unknown in part due to a lack of animal models of cardiac pathology in which carnitine derivatives improve exercise tolerance. Our goal was to evaluate the ability of propionyl-L-carnitine (PLC) to improve exercise tolerance in a rat model of exercise intolerance. Fischer 344 rats were followed after either a moderate size MI (n = 22) or sham MI surgery (n = 14). Starting 10 days post-surgery 10 of the MI and 7 of the sham rats received 100 mg/kg/day PLC in drinking water, which increased plasma and LV total 1-carnitine concentrations 15-23{\%} (p < 0.05). Rats were followed longitudinally until a statistically significant decrease in exercise capacity occurred in one of the groups, at which time all rats were sacrificed for study of the isolated perfused hearts. At 12-weeks post-MI exercise capacity had decreased 16 ± 7{\%} (p < 0.05) in the MI group, but remained within 3{\%} of baseline in the MI group that received PLC and the sham groups. Both MI groups exhibited the same degree of LV dilation, decrease in fractional shortening, and blunting of the response to isoproterenol. We conclude that supplemental dietary PLC attenuates the exercise intolerance that occurs secondary to post-MI heart failure in rats, but that this beneficial effect is not attributable to altered LV remodeling, an improved response to β-adrenergic stimulation, or increased skeletal muscle citrate synthase activity.",
author = "Koh, {Stanley G.} and Brenner, {Daniel A.} and Korzick, {Donna Hope} and Tickerhoof, {Marlena M.} and Apstein, {Carl S.} and Saupe, {Kurt W.}",
year = "2003",
month = "8",
day = "5",
doi = "10.1023/A:1024247507014",
language = "English (US)",
volume = "17",
pages = "7--14",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "1",

}

Exercise intolerance during post-MI heart failure in rats : Prevention with supplemental dietary propionyl-L-carnitine. / Koh, Stanley G.; Brenner, Daniel A.; Korzick, Donna Hope; Tickerhoof, Marlena M.; Apstein, Carl S.; Saupe, Kurt W.

In: Cardiovascular Drugs and Therapy, Vol. 17, No. 1, 05.08.2003, p. 7-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Exercise intolerance during post-MI heart failure in rats

T2 - Prevention with supplemental dietary propionyl-L-carnitine

AU - Koh, Stanley G.

AU - Brenner, Daniel A.

AU - Korzick, Donna Hope

AU - Tickerhoof, Marlena M.

AU - Apstein, Carl S.

AU - Saupe, Kurt W.

PY - 2003/8/5

Y1 - 2003/8/5

N2 - Summary. Exercise capacity in patients with several types of cardiovascular disease can be improved with dietary carnitine, or carnitine derivatives. Mechanisms underlying this improvement remain largely unknown in part due to a lack of animal models of cardiac pathology in which carnitine derivatives improve exercise tolerance. Our goal was to evaluate the ability of propionyl-L-carnitine (PLC) to improve exercise tolerance in a rat model of exercise intolerance. Fischer 344 rats were followed after either a moderate size MI (n = 22) or sham MI surgery (n = 14). Starting 10 days post-surgery 10 of the MI and 7 of the sham rats received 100 mg/kg/day PLC in drinking water, which increased plasma and LV total 1-carnitine concentrations 15-23% (p < 0.05). Rats were followed longitudinally until a statistically significant decrease in exercise capacity occurred in one of the groups, at which time all rats were sacrificed for study of the isolated perfused hearts. At 12-weeks post-MI exercise capacity had decreased 16 ± 7% (p < 0.05) in the MI group, but remained within 3% of baseline in the MI group that received PLC and the sham groups. Both MI groups exhibited the same degree of LV dilation, decrease in fractional shortening, and blunting of the response to isoproterenol. We conclude that supplemental dietary PLC attenuates the exercise intolerance that occurs secondary to post-MI heart failure in rats, but that this beneficial effect is not attributable to altered LV remodeling, an improved response to β-adrenergic stimulation, or increased skeletal muscle citrate synthase activity.

AB - Summary. Exercise capacity in patients with several types of cardiovascular disease can be improved with dietary carnitine, or carnitine derivatives. Mechanisms underlying this improvement remain largely unknown in part due to a lack of animal models of cardiac pathology in which carnitine derivatives improve exercise tolerance. Our goal was to evaluate the ability of propionyl-L-carnitine (PLC) to improve exercise tolerance in a rat model of exercise intolerance. Fischer 344 rats were followed after either a moderate size MI (n = 22) or sham MI surgery (n = 14). Starting 10 days post-surgery 10 of the MI and 7 of the sham rats received 100 mg/kg/day PLC in drinking water, which increased plasma and LV total 1-carnitine concentrations 15-23% (p < 0.05). Rats were followed longitudinally until a statistically significant decrease in exercise capacity occurred in one of the groups, at which time all rats were sacrificed for study of the isolated perfused hearts. At 12-weeks post-MI exercise capacity had decreased 16 ± 7% (p < 0.05) in the MI group, but remained within 3% of baseline in the MI group that received PLC and the sham groups. Both MI groups exhibited the same degree of LV dilation, decrease in fractional shortening, and blunting of the response to isoproterenol. We conclude that supplemental dietary PLC attenuates the exercise intolerance that occurs secondary to post-MI heart failure in rats, but that this beneficial effect is not attributable to altered LV remodeling, an improved response to β-adrenergic stimulation, or increased skeletal muscle citrate synthase activity.

UR - http://www.scopus.com/inward/record.url?scp=0042371703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042371703&partnerID=8YFLogxK

U2 - 10.1023/A:1024247507014

DO - 10.1023/A:1024247507014

M3 - Article

C2 - 12843682

AN - SCOPUS:0042371703

VL - 17

SP - 7

EP - 14

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 1

ER -